360° Coverage : Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at...

1 Updates

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is...

Filed under: news

YouTube Videos

 
 
 

1 year ago

Paid Rheumatoid Arthritis (RA) Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with RA Age 18 - 75

Oct 16 2013, 4:18pm CDT | by PR.com

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA).

Birmingham, AL, October 16, 2013 --(PR.com)-- *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/). There is no cost to participate, no insurance is required, and you may receive compensation for time and travel.

Study Design

This is a 48-week, double-blind, multiple dose, parallel group trial to compare the safety, efficacy, immunogenicity and tolerability of an experimental drug to Rituxan and MabThera in patients with moderately to severely active RA. Patients will be enrolled across 250 clinical sites, in 26 countries.

Part I (48-week duration) will include 150 patients, which is considered sufficient for pharmacokinetics (PK) testing. Part II consists of a 48-week comparative safety/efficacy analyses with an additional 150 patients.

Background & Rationale

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by synovial inflammation in the joints and consequently, progressive joint destruction. Depending on the severity of the disease, systemic manifestations may occur including lung disease, rheumatoid nodules and cardiovascular system effects. Without effective RA treatment, this disease may lead to severe functional disabilities, and therefore a considerable reduction in quality of life for the patient. The prevalence of RA varies with factors such as gender, race and smoking status and is approximately 0.5-1%.

B lymphocytes (B cells) are thought to play a crucial role in the pathogenesis of RA. They are also the primary source of rheumatoid factors (RFs) and anti-cyclic citrullinated peptide (anti-CCP) antibodies which contribute to the formation of immune complexes and complement activation in inflamed joints. Thus, B cell targeted therapy could play an important role in RA through a reduction in the B cell count as well as a reduction in B cell-mediated downstream effects on other cell types involved in the inflammatory response.

Primary Objectives

The primary objectives of this trial are:

To show PK similarity of this new drug to MabThera and Rituxan and of Rituxan to MabThera (three-way PK similarity).
To establish statistical equivalence of efficacy of this new drug and Rituxan/MabThera, in patients with moderately to severely active RA

Inclusion Criteria

Male or female participants, between 18 and 80 years of age, who have a diagnosis of moderately to severely active RA for at least 6 months

Patients must have had an inadequate response or intolerance to conventional DMARD therapy including at least one TNF inhibitor.

Positive for RF and/or anti-CCP antibodies.

Current treatment for RA on an outpatient basis:

-- Must be currently receiving and tolerating oral or parenteral MTX therapy at a dose of 15-25 mg per week (dose may be as low as 10 mg per week if the patient is unable to tolerate a higher dose) for at least 12 weeks immediately prior to Day 1.

-- Patients must be willing to receive oral folic acid (at least 5 mg/week or as per local practice) or equivalent during the entire study (mandatory co-medication for MTX treatment).

-- Biologic agents and DMARDs (other than MTX) must be withdrawn at least 2 weeks prior to Day 1.

-- Leflunomide must be withdrawn at least 8 weeks prior to Day 1 or a minimum of 2 weeks prior to Day 1 if after 11 days of standard cholestyramine washout.

-- If receiving current treatment with oral corticosteroids (other than intra-articular or parenteral), the dose must not exceed 10 mg/day prednisolone or equivalent. During the 4 weeks prior to Baseline (Day 1) the dose must remain stable.

-- Intra-articular and parenteral corticosteroids are not permitted within 6 weeks prior to Baseline Day 1 or throughout the trial, with the exception of IV administration of 100 mg methylprednisolone 30 to 60 minutes prior to each infusion
as this is part of the trial procedures.

-- Any concomitant non-steroidal anti-inflammatory drugs (NSAIDs) must be stable for at least 2 weeks prior to Day 1.

-- Patients may be taking oral hydroxychloroquine provided that the dose is not greater than 400 mg/day or chloroquine provided that the dose is not greater than 250 mg/day.

*Achieve Clinical Research conducts Phase II-IV Clinical Trials in Alabama. For more information about participating in an RA Clinical Study, please visit our website or contact us directly at (205) 380-6434.

Contact Information:
Achieve Clinical Research
Lashondra Cade
(205) 380-6434 320
Contact via Email
www.achieveclinical.com

Read the full story here: http://www.pr.com/press-release/520216

Press Release Distributed by PR.com

Source: PR.com

 

Don't miss ...

 

blog comments powered by Disqus

Latest stories

Veteran journalists hail innovations in world media awards
Beijing, Oct 27 (Xinhua) Winners of the World Media Summit (WMS) Global Awards for Excellence 2014 were announced Monday, including reports on Myanmar and killing sprees in America.
 
 
Chinese lunar orbiter prepares to return home
Beijing, Oct 27 (IANS) An experimental Chinese spacecraft, designed to fly around the moon and back to earth, entered lunar orbit Monday and is making necessary preparations for its trip back home.
 
 
Child tested for Ebola in New York hospital
New York, Oct 27 (IANS/EFE) A five-year-old boy who recently arrived in the US from West Africa was admitted to a New York hospital with a fever and is being tested for the presence of the Ebola virus, media reported Monday.
 
 
Cuba rules out Ebola for expert's death in Guinea
Havana, Oct 27 (IANS) A Cuban expert who died in Guinea was not infected with the Ebola virus, the Cuban health ministry said Monday.
 
 
 

Latest from the Network

Russia to recognise results of Ukraine parliamentary elections
Moscow, Oct 28 (IANS/EFE) Russian Foreign Minister Sergey Lavrov said Monday that his country will recognise the results of Sunday's parliamentary elections in Ukraine, where pro-European parties won a convincing...
Read more on Politics Balla
 
India, Belgium underscore friendly ties
Brussels, Oct 27 (IANS) Minister of State for External Affairs Gen. (retd) V.K. Singh Monday met Belgium's Deputy Prime Minister and Foreign Minister Didier Reynders, the Indian embassy said. According to an embassy...
Read more on Politics Balla
 
Israel PM orders harsher penalties for stone-pelters
Jerusalem, Oct 27 (IANS) Israel's Prime Minister Benjamin Netanyahu Monday met law enforcement officials and legal experts over the escalating violence in Arab east Jerusalem, ordering the judiciary to expedite...
Read more on Politics Balla
 
Taylor Swift named NYC Global Welcome Ambassador
Taylor Swift has been named New York City's Global Welcome Ambassador. The 24-year-old singer has joined forces with NYC & Company - the city's official marketing, tourism and partnership organisation - to...
Read more on Celebrity Balla
 
Halle Berry's husband 'calls her out' on clothing
Halle Berry's husband Olivier Martinez ''calls her out'' on her clothing if he doesn't like what she's wearing. The 48-year-old actress has admitted she has become a lot more careful about what she wears since tying the...
Read more on Celebrity Balla
 
Kate Bush former home up for sale for £3m
Kate Bush's former home is up for sale for £3 million. The property on Eltham's Court Road in London, south east England - where the 'Wuthering Heights' hitmaker lived for nearly twenty years from 1985 until 2003 - has...
Read more on Celebrity Balla
 
Bruce Jenner gives Kris Jenner $4m home in divorce case
Bruce Jenner is giving his share of his $4 million marital home to Kris Jenner as part of their divorce settlement. The couple acquired the six-bedroom property in Hidden Hills, California, for the sum in 2010, but the...
Read more on Celebrity Balla
 
EU leaders welcome Ukraine parliamentary polls
Brussels, Oct 27 (IANS) The European Union Monday welcomed Ukraine's parliamentary elections, and said they expected the early formation of a new government. "A reinvigorated reform process, including the launching of...
Read more on Politics Balla
 
Obama congratulates Ukrainians for 'successful' elections
Washington, Oct 27 (IANS) US President Barack Obama congratulated the people of Ukraine on holding "successful" parliamentary elections, the White House said Monday. "Despite a challenging security environment in...
Read more on Politics Balla
 
The Stores of CVS and Rite Aid Stop Supporting Apple Pay
The expansion of the service of Apple Pay has been interrupted, as the two major drug stores, called CVS and Rite Aid, decide not to provide support for Apple Pay any long.According to Mac Rumors, both the companies...
Read more on Apple Balla